Albumin is the most abundant circulating protein in plasma and has recently emerged as a versatile protein carrier for drug targeting and for improving the pharmacokinetic profile of peptide or protein based drugs. Three drug delivery technologies related to albumin have been developed, which include the coupling of low-molecular weight drugs to exogenous or endogenous albumin, conjugating bioactive proteins by albumin fusion technology (AFT), and encapsulation of drugs into albumin nanoparticles. This lecture starts with a brief introduction of human serum albumin (HSA), and then summarizes the mainstream chemical strategies of developing HSA binding molecules for coupling with drug molecules. The recent use of Evans blue dye conjugates as molecular imaging probes and long-acting drug formulation will be highlighted.  Moreover, the most important clinical applications of HSA-binding platforms will be discussed and the current challenges that need to be met for a bright future of HSA-binding will be specified.<br/>

Albumin based bioconjugates for diagnosis and precision therapy

252nd National Meeting (2016)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.